YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YIHCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,724 | $6,295 | $3,745 | $914 |
| % Growth | -40.8% | 68.1% | 309.8% | – |
| Cost of Goods Sold | $930 | $1,309 | $899 | $430 |
| Gross Profit | $2,794 | $4,986 | $2,846 | $484 |
| % Margin | 75% | 79.2% | 76% | 52.9% |
| R&D Expenses | $493 | $192 | $130 | $137 |
| G&A Expenses | $385 | $386 | $338 | $358 |
| SG&A Expenses | $1,539 | $1,939 | $1,551 | $883 |
| Sales & Mktg Exp. | $1,154 | $1,547 | $1,217 | $522 |
| Other Operating Expenses | $87 | $500 | $0 | $0 |
| Operating Expenses | $2,120 | $2,632 | $2,532 | $918 |
| Operating Income | $674 | $2,354 | $323 | -$458 |
| % Margin | 18.1% | 37.4% | 8.6% | -50.1% |
| Other Income/Exp. Net | -$97 | -$227 | -$282 | -$244 |
| Pre-Tax Income | $577 | $2,127 | $39 | -$667 |
| Tax Expense | $95 | $271 | -$10 | -$79 |
| Net Income | $483 | $1,993 | $77 | -$588 |
| % Margin | 13% | 31.7% | 2% | -64.3% |
| EPS | 0.55 | 2.26 | 0.087 | -0.67 |
| % Growth | -75.7% | 2,494.7% | 113% | – |
| EPS Diluted | 0.55 | 2.26 | 0.087 | -0.67 |
| Weighted Avg Shares Out | 880 | 882 | 880 | 877 |
| Weighted Avg Shares Out Dil | 880 | 880 | 880 | 880 |
| Supplemental Information | – | – | – | – |
| Interest Income | $70 | $58 | $7 | $11 |
| Interest Expense | $98 | $227 | $282 | $244 |
| Depreciation & Amortization | $396 | $391 | $377 | $260 |
| EBITDA | $1,070 | $2,745 | $691 | -$207 |
| % Margin | 28.7% | 43.6% | 18.5% | -22.6% |